141 related articles for article (PubMed ID: 12706368)
1. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology.
Baker EA; Leaper DJ
Eur J Cancer; 2003 May; 39(7):981-8. PubMed ID: 12706368
[TBL] [Abstract][Full Text] [Related]
2. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Baker EA; Bergin FG; Leaper DJ
Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
5. Proteolysis in colorectal cancer.
Garbett EA; Reed MW; Brown NJ
Mol Pathol; 1999 Jun; 52(3):140-5. PubMed ID: 10621835
[TBL] [Abstract][Full Text] [Related]
6. The effect of IL-1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells.
Fujisaki K; Tanabe N; Suzuki N; Mitsui N; Oka H; Ito K; Maeno M
Life Sci; 2006 Mar; 78(17):1975-82. PubMed ID: 16313928
[TBL] [Abstract][Full Text] [Related]
7. Expression of proteinases and inhibitors in human breast cancer progression and survival.
Baker EA; Stephenson TJ; Reed MW; Brown NJ
Mol Pathol; 2002 Oct; 55(5):300-4. PubMed ID: 12354933
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
9. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation.
Badier-Commander C; Verbeuren T; Lebard C; Michel JB; Jacob MP
J Pathol; 2000 Sep; 192(1):105-12. PubMed ID: 10951407
[TBL] [Abstract][Full Text] [Related]
10. [The expression of matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinases (TIMPs) and angiogenesis in relation to the depth of tumor invasion and lymph node metastasis in submucosally invasive colorectal carcinoma].
Jung SA; Yang SK; Kim JS; Shim KN; Im SA; Myung SJ; Jung HY; Yu CS; Kim JC; Hong WS; Kim JH; Min YI
Korean J Gastroenterol; 2005 Jun; 45(6):401-8. PubMed ID: 15973074
[TBL] [Abstract][Full Text] [Related]
11. Proteinases, their inhibitors, and cytokine profiles in acute wound fluid.
Baker EA; Leaper DJ
Wound Repair Regen; 2000; 8(5):392-8. PubMed ID: 11115151
[TBL] [Abstract][Full Text] [Related]
12. Proteolysis in human breast and colorectal cancer.
Garbett EA; Reed MW; Brown NJ
Br J Cancer; 1999 Sep; 81(2):287-93. PubMed ID: 10496354
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
14. Effect of the luteinising hormone surge on regulation of vascular endothelial growth factor and extracellular matrix-degrading proteinases and their inhibitors in bovine follicles.
Berisha B; Steffl M; Welter H; Kliem H; Meyer HH; Schams D; Amselgruber W
Reprod Fertil Dev; 2008; 20(2):258-68. PubMed ID: 18255015
[TBL] [Abstract][Full Text] [Related]
15. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
16. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.
Baricos WH; Cortez SL; el-Dahr SS; Schnaper HW
Kidney Int; 1995 Apr; 47(4):1039-47. PubMed ID: 7540230
[TBL] [Abstract][Full Text] [Related]
17. Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human colorectal, pancreatic and hepatic carcinoma cell lines.
Roomi MW; Kalinovsky T; Niedzwiecki A; Rath M
Int J Oncol; 2015 Jul; 47(1):370-6. PubMed ID: 25997494
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Curran S; Dundas SR; Buxton J; Leeman MF; Ramsay R; Murray GI
Clin Cancer Res; 2004 Dec; 10(24):8229-34. PubMed ID: 15623598
[TBL] [Abstract][Full Text] [Related]
19. Profiles of matrix metalloproteinases and their tissue inhibitors in intraperitoneal drainage fluid: relationship to wound healing.
Baker EA; Leaper DJ
Wound Repair Regen; 2003; 11(4):268-74. PubMed ID: 12846914
[TBL] [Abstract][Full Text] [Related]
20. The matrix metalloproteinase system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2006 Dec; 44(6):482-6. PubMed ID: 16338034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
